Collegium Pharmaceutical Inc (NAS:COLL)
$ 30.71 -0.48 (-1.54%) Market Cap: 990.40 Mil Enterprise Value: 1.74 Bil PE Ratio: 13.18 PB Ratio: 4.22 GF Score: 80/100

Q2 2019 Collegium Pharmaceutical Inc Earnings Call Transcript

Aug 07, 2019 / 08:30PM GMT
Release Date Price: $10.61 (-0.93%)
Operator

Good day, and welcome to the Q2 2019 Collegium Pharmaceutical Earnings Conference Call. I will now turn the call over to Alex Dasalla. You may begin.

Alex Dasalla
Collegium Pharmaceutical, Inc. - Head of IR

Welcome to the Collegium Pharmaceutical's Second Quarter 2019 Earnings Conference Call. This is Alex Dasalla, Head of Investor Relations for Collegium. I am joined today by Joe Ciaffoni, our Chief Executive Officer; Paul Brannelly, our Chief Financial Officer; and Scott Dreyer, our Chief Commercial Officer.

Before we begin today's call, we want to remind participants that none of the information presented today is intended to be promotional, and that any forward-looking statements made today are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. You are cautioned that such forward-looking statements involve risks and uncertainties, including and without limitation, the risks that we may not be able to successfully commercialize Xtampza ER and the Nucynta franchise, and that we will incur significant

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot